# A Study to Assess the Efficacy, Safety, Pharmacodynamics, and Pharmacokinetics of Tazemetostat in Combination With Lenalidomide Plus Rituximab Versus Placebo in Combination With Lenalidomide Plus Rituximab in Adult Patients at Least 18 Years of Age With Relapsed/Refractory Follicular Lymphoma.

> **NCT04224493** · PHASE3 · ACTIVE_NOT_RECRUITING · sponsor: **Epizyme, Inc.** · enrollment: 555 (actual)

## Conditions studied

- Relapsed/Refractory Follicular Lymphoma
- Follicular Lymphoma
- Refractory Follicular Lymphoma

## Interventions

- **DRUG:** Tazemetostat
- **DRUG:** Tazemetostat
- **DRUG:** Placebo oral tablet
- **COMBINATION_PRODUCT:** Lenalidomide
- **COMBINATION_PRODUCT:** Rituximab

## Key facts

- **NCT ID:** NCT04224493
- **Lead sponsor:** Epizyme, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2020-06-11
- **Primary completion:** 2027-02-13
- **Final completion:** 2029-03-01
- **Target enrollment:** 555 (ACTUAL)
- **Last updated:** 2026-04-20


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04224493

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04224493, "A Study to Assess the Efficacy, Safety, Pharmacodynamics, and Pharmacokinetics of Tazemetostat in Combination With Lenalidomide Plus Rituximab Versus Placebo in Combination With Lenalidomide Plus Rituximab in Adult Patients at Least 18 Years of Age With Relapsed/Refractory Follicular Lymphoma.". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT04224493. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*